guest ::
| Home > Publications database > Epstein-Barr virus (EBV) serology and its impact on oral human papillomavirus (HPV) infection outcomes in children during early childhood. > print |
| Home > Publications database > Epstein-Barr virus (EBV) serology and its impact on oral human papillomavirus (HPV) infection outcomes in children during early childhood. > print |
| 001 | 303473 | ||
| 005 | 20250904143121.0 | ||
| 024 | 7 | _ | |a 10.1128/spectrum.00071-25 |2 doi |
| 024 | 7 | _ | |a pmid:40748074 |2 pmid |
| 037 | _ | _ | |a DKFZ-2025-01670 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 570 |
| 100 | 1 | _ | |a Rinne, Sanni |0 0009-0002-8268-7485 |b 0 |
| 245 | _ | _ | |a Epstein-Barr virus (EBV) serology and its impact on oral human papillomavirus (HPV) infection outcomes in children during early childhood. |
| 260 | _ | _ | |a Birmingham, Ala. |c 2025 |b ASM |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1756989048_27122 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a 2025 Sep 2;13(9):e0007125 |
| 520 | _ | _ | |a Epstein-Barr virus (EBV) and various human papillomaviruses (HPVs) commonly infect the oral mucosa, yet the longitudinal effects of these infections and their potential coinfections remain poorly understood. This study investigated whether early EBV infection and antibody responses influence oral HPV infections in young children. We included 283 children from the Finnish Family HPV cohort study, who were followed for 3 years post-birth. Oral and blood samples were collected at six time points (1, 2, 6, 12, 24, and 36 months). HPV genotyping was performed with Luminex and EBV-IgG antibodies to Zebra, early antigen-diffuse (EA-D), EBV nuclear antigen 1, and viral capsid antigen p18 with fluorescent bead-based multiplex serology. We noticed that most children (91.4%; n = 254) experienced the vanishing of maternal EBV-IgG antibodies within 11.3 months, and by 36 months, 17% (41/238) of the children had developed their own EBV antibodies. Intriguingly, higher paternal education levels were strongly associated with lower EBV seropositivity in children at ages 2 and 3, with an odds ratio(OR) range of 0.06 to 0.16 (95% confidence interval range 0.005-0.91). Additionally, children with the highest baseline titers of EA-D antibodies had 2.5- and threefold risk for incident oral HPV infection and its clearance, respectively. Our findings suggest that EBV seropositivity at 3 years of age is relatively low in our Finnish data, and the level of paternal education was a significant protective factor against early EBV seropositivity. Moreover, the observed association between high EA-D antibody titers and oral HPV infection underscores the need for further research into the complex interactions between EBV and HPV.IMPORTANCEEpstein-Barr virus (EBV) and human papillomaviruses (HPVs) are known to cause cancers in the head and neck region, yet their interactions in young children remain largely unexplored. EBV, associated with infectious mononucleosis, and oral HPV, often asymptomatic in early childhood, target similar anatomical regions but are poorly studied together in this age group. Understanding these interactions is crucial, as the incidence of HPV-related oropharyngeal cancers has been rising over recent decades, making the natural history of oral HPV infections a critical research focus. While our study found no significant link between EBV seropositivity and oral HPV outcomes in children, evidence in adults suggests these viruses may interact in cancer development. Investigating this dynamic in early childhood could provide valuable insights into infection patterns and inform prevention strategies to reduce cancer risks later in life. |
| 536 | _ | _ | |a 314 - Immunologie und Krebs (POF4-314) |0 G:(DE-HGF)POF4-314 |c POF4-314 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a EBV serology |2 Other |
| 650 | _ | 7 | |a Epstein-Barr virus |2 Other |
| 650 | _ | 7 | |a children |2 Other |
| 650 | _ | 7 | |a human papillomavirus |2 Other |
| 650 | _ | 7 | |a oral HPV infection |2 Other |
| 700 | 1 | _ | |a Michels, Birgitta |0 P:(DE-He78)b48bfd64120195b64b5f11d32ce5ed5e |b 1 |u dkfz |
| 700 | 1 | _ | |a Butt, Julia |0 P:(DE-He78)31d7c3e829be03400641f80b821ef728 |b 2 |u dkfz |
| 700 | 1 | _ | |a Syrjänen, Kari |b 3 |
| 700 | 1 | _ | |a Grenman, Seija |b 4 |
| 700 | 1 | _ | |a Waterboer, Tim |0 P:(DE-He78)6b4ebb9791b983b5620c0caaf3468e30 |b 5 |u dkfz |
| 700 | 1 | _ | |a Syrjänen, Stina |b 6 |
| 700 | 1 | _ | |a Louvanto, Karolina |0 0000-0002-1172-363X |b 7 |
| 773 | _ | _ | |a 10.1128/spectrum.00071-25 |g p. e00071-25 |0 PERI:(DE-600)2807133-5 |n 9 |p e0007125 |t Microbiology spectrum |v 13 |y 2025 |x 2165-0497 |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:303473 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 1 |6 P:(DE-He78)b48bfd64120195b64b5f11d32ce5ed5e |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 2 |6 P:(DE-He78)31d7c3e829be03400641f80b821ef728 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 5 |6 P:(DE-He78)6b4ebb9791b983b5620c0caaf3468e30 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-314 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Immunologie und Krebs |x 0 |
| 914 | 1 | _ | |y 2025 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b MICROBIOL SPECTR : 2022 |d 2024-12-27 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2024-12-27 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2024-12-27 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0501 |2 StatID |b DOAJ Seal |d 2022-02-02T17:55:23Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0500 |2 StatID |b DOAJ |d 2022-02-02T17:55:23Z |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b DOAJ : Peer review, Anonymous peer review |d 2022-02-02T17:55:23Z |
| 915 | _ | _ | |a Creative Commons Attribution CC BY (No Version) |0 LIC:(DE-HGF)CCBYNV |2 V:(DE-HGF) |b DOAJ |d 2022-02-02T17:55:23Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2024-12-27 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2024-12-27 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2024-12-27 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2024-12-27 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1120 |2 StatID |b BIOSIS Reviews Reports And Meetings |d 2024-12-27 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2024-12-27 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2024-12-27 |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |d 2024-12-27 |
| 915 | _ | _ | |a Article Processing Charges |0 StatID:(DE-HGF)0561 |2 StatID |d 2024-12-27 |
| 915 | _ | _ | |a Fees |0 StatID:(DE-HGF)0700 |2 StatID |d 2024-12-27 |
| 920 | 1 | _ | |0 I:(DE-He78)D320-20160331 |k D320 |l Infektionen und Krebs-Epidemiologie |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)D320-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|